All In Biotech

Drug Trial Radar · NCT07095452

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Subjects With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Mar 2041

Study completion Jan 2042

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
IFM (Intergroupe Français du Myélome); PETHEMA (Program for the Study and Treatment of Haematological Malignances)
First posted
Jul 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change in disease activity, and pharmacokinetics of Etentamig in adult participants with MM. Etentamig is an investigational drug being developed for the treatment of MM. This study is broken into 2 phases; a phase 2 dose selection and optimization cohort with 3 study arms and a subcutaneous (SC) safety cohort with 2 study arms. Phase 3 participants will receive etentamig at recommended Phase 3 dose (RP3D). Around 680 adult participants with MM will be enrolled at approximately 155 sites worldwide Participants in the phase 2 dose selection and optimization cohort will receive 1 of 3 doses of etentamig as intravenous (IV) infusions, combination with subcutaneous (SC) injections of daratumumab. The Phase 2 subcutaneous (SC) safety cohort participants will receive 1 of 2 doses of etentamig in combination with daratumumab. Participants in phase 3 will receive RP3D doses of etentamig as IV infusions, combination with SC injections of daratumumab, or SC injections of daratumumab, capsules of lenalidomide, and tablet/ IV injections of dexamethasone (DRd). The study duration is approximately 16 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and questionnaires.

Conditions

  • Multiple Myeloma

Interventions

  • EtentamigDrug

    Intravenous (IV) Infusion

  • LenalidomideDrug

    Oral Capsule

  • DaratumumabDrug

    Subcutaneous Injection

  • DexamethasoneDrug

    Oral Tablet

  • DexamethasoneDrug

    IV Injection

  • EtentamigDrug

    Subcutaneous Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 and 3: Percentage of Participants with Adverse Events (AE)sTime frame: Up to Approximately 16 Years
  2. Phase 2: Change in Clinical ActivityTime frame: Up to Approximately 52 weeks
  3. Phase 3: Minimal Residual Disease (MRD) Negative CR RateTime frame: Up to Approximately 52 weeks
  4. Phase 3: Progression-Free Survival (PFS)Time frame: Up to Approximately 130 Months

Locations

49 sites in 4 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital Scottsdale /ID# 278349

    Scottsdale, Arizona · Recruiting

  • Cedars-Sinai Medical Center /ID# 278238

    Los Angeles, California · Recruiting

  • Colorado Blood Cancer Institute /ID# 279080

    Denver, Colorado · Recruiting

  • Winship Cancer Institute of Emory University /ID# 277667

    Atlanta, Georgia · Recruiting

  • Fort Wayne Medical Oncology And Hematology /ID# 278141

    Fort Wayne, Indiana · Recruiting

  • Minnesota Oncology - Minneapolis Clinic /ID# 278720

    Minneapolis, Minnesota · Recruiting

  • Mayo Clinic Hospital Rochester /ID# 277886

    Rochester, Minnesota · Recruiting

  • Icahn School of Medicine at Mount Sinai /ID# 277844

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 277946

    New York, New York · Recruiting

  • Weill Cornell Medicine Myeloma Center /ID# 278216

    New York, New York · Recruiting

  • University of North Carolina at Chapel Hill /ID# 277708

    Chapel Hill, North Carolina · Recruiting

  • Willamette Valley Cancer Institute and Research Center /ID# 278721

    Eugene, Oregon · Recruiting

  • SCRI Oncology Partners /ID# 278353

    Nashville, Tennessee · Recruiting

  • Texas Oncology - The Woodlands /ID# 278726

    The Woodlands, Texas · Recruiting

  • Texas Oncology - Northeast Texas /ID# 278725

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 278716

    Fairfax, Virginia · Recruiting

  • Blue Ridge Cancer Care - Roanoke /ID# 278722

    Roanoke, Virginia · Recruiting

  • Hopital Saint-Louis /ID# 278429

    Paris, France · Recruiting

  • Hopital Saint Antoine /ID# 278428

    Paris, France · Recruiting

  • Centre Hospitalier Annecy Genevois /ID# 278406

    Epagny Metz Tessy, Auvergne-Rhône-Alpes, France · Recruiting

  • Centre Hospitalier De Dunkerque-Hospital Alexandra Lepeve /ID# 278399

    Dunkirk, Hauts-de-France, France · Recruiting

  • Chu De Lille - Hopital Claude Huriez /ID# 278413

    Lille, Hauts-de-France, France · Recruiting

  • CHU de Montpellier - Hopital Saint Eloi /ID# 278415

    Montpellier, Herault, France · Recruiting

  • Hopital Universitaire Necker Enfants Malades /ID# 278426

    Paris, Île-de-France Region, France · Recruiting

  • CHRU Tours - Hopital Bretonneau /ID# 279274

    Tours, Indre-et-Loire, France · Recruiting

  • CH Bretagne Atlantique /ID# 278422

    Vannes, Morbihan, France · Recruiting

  • Centre Hospitalier Universitaire de Bordeaux /ID# 278419

    Pessac, New Aquitaine, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers /ID# 278398

    Poitiers, New Aquitaine, France · Recruiting

  • IUCT Oncopole /ID# 278403

    Toulouse, Occitanie, France · Recruiting

  • Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 278402

    Nantes, Pays de la Loire Region, France · Recruiting

  • Centre Hospitalier Universitaire de Saint Etienne - Hopital Nord /ID# 278421

    St-Priest-en-Jarez, Pays de la Loire Region, France · Recruiting

  • HCL - Hopital Lyon Sud /ID# 282145

    Pierre-Bénite, Rhone, France · Recruiting

  • Nagoya City University Hospital /ID# 278188

    Nagoya, Aichi-ken, Japan · Recruiting

  • Matsuyama Red Cross Hospital /ID# 278660

    Matsuyama, Ehime, Japan · Recruiting

  • Kurume University Hospital /ID# 278209

    Kurume-shi, Fukuoka, Japan · Recruiting

  • Tokai University Hospital /ID# 278157

    Isehara, Kanagawa, Japan · Recruiting

  • University Hospital Kyoto Prefectural University of Medicine /ID# 278156

    Kyoto, Kyoto, Japan · Recruiting

  • Hospital Clinic de Barcelona /ID# 278532

    Barcelona, Spain · Recruiting

  • Complejo Asistencial Universitario de Leon - Hospital de Leon /ID# 278534

    León, Spain · Recruiting

  • Hospital General Universitario Gregorio Maranon /ID# 278551

    Madrid, Spain · Recruiting

Showing 40 of 49 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.